These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 24594069)
1. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience. Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069 [TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura. Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905 [TBL] [Abstract][Full Text] [Related]
4. Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. Schiavotto C; Castaman G; Rodeghiero F Haematologica; 1993; 78(6 Suppl 2):29-34. PubMed ID: 8039755 [TBL] [Abstract][Full Text] [Related]
5. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J; Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322 [TBL] [Abstract][Full Text] [Related]
6. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Godeau B; Porcher R; Fain O; Lefrère F; Fenaux P; Cheze S; Vekhoff A; Chauveheid MP; Stirnemann J; Galicier L; Bourgeois E; Haiat S; Varet B; Leporrier M; Papo T; Khellaf M; Michel M; Bierling P Blood; 2008 Aug; 112(4):999-1004. PubMed ID: 18463354 [TBL] [Abstract][Full Text] [Related]
7. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Schweizer C; Reu FJ; Ho AD; Hensel M Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529 [TBL] [Abstract][Full Text] [Related]
8. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults. Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557 [TBL] [Abstract][Full Text] [Related]
11. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience. Al Askar AS; Shaheen NA; Al Zahrani M; Al Otaibi MG; Al Qahtani BS; Ahmed F; Al Zughaibi M; Kamran I; Mendoza MA; Khan A Int J Hematol; 2018 Jan; 107(1):69-74. PubMed ID: 28895035 [TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Giagounidis AA; Anhuf J; Schneider P; Germing U; Söhngen D; Quabeck K; Aul C Eur J Haematol; 2002 Aug; 69(2):95-100. PubMed ID: 12366712 [TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Colović M; Suvajdzic N; Colović N; Tomin D; Vidović A; Palibrk V Platelets; 2011; 22(2):153-6. PubMed ID: 21142405 [TBL] [Abstract][Full Text] [Related]
14. [Reference guide for the treatment of adult idiopathic thrombocytopenic purpura]. Kashiwagi H Rinsho Ketsueki; 2020; 61(9):1325-1330. PubMed ID: 33162532 [TBL] [Abstract][Full Text] [Related]
15. Splenectomy results in patients with idiopathic thrombocytopenic purpura: 10 years of experience in Turgut Ozal Medical Center. Ismet A; Irfan K; Emin K; AlI EM; Ramazan U; Mustafa B; Onur O Clin Lab Haematol; 2004 Jun; 26(3):211-4. PubMed ID: 15163320 [TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147 [TBL] [Abstract][Full Text] [Related]
17. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Pamuk GE; Pamuk ON; Başlar Z; Ongören S; Soysal T; Ferhanoğlu B; Aydin Y; Ulkü B; Aktuğlu G; Akman N Ann Hematol; 2002 Aug; 81(8):436-40. PubMed ID: 12224000 [TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes in adults with chronic ITP after splenectomy failure. McMillan R; Durette C Blood; 2004 Aug; 104(4):956-60. PubMed ID: 15100149 [TBL] [Abstract][Full Text] [Related]
19. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR; Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390 [TBL] [Abstract][Full Text] [Related]
20. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura. Pasa S; Altintas A; Cil T; Danis R; Ayyildiz O J Thromb Thrombolysis; 2009 Apr; 27(3):329-33. PubMed ID: 18311541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]